The US's withdrawal from the Joint Plan of Action with Iran and the reimposition of sanctions can impact Danish pharmaceutical companies and medico firms, writes the Danish interest group Dansk Industri. Novo Nordisk, which has invested DKK 500 million (EUR 67 million) in Iran, awaits further developments.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.